On Friday, this biotech company, my first pick for this newsletter, in October 2013, hit $52.40, a more than 400% return from my initial recommended price of $10.42 -‑ all in 20 months.
On Friday, this biotech company, my first pick for this newsletter, in October 2013, hit $52.40, a more than 400% return from my initial recommended price of $10.42 -‑ all in 20 months.